Do amyloid-targeting monoclonal antibodies (mAbs) exhibit varying efficacy between males and females?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 6, 2025 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Amyloid monoclonal antibodies do not have established varying efficacy between sexes based on the provided evidence. The most recent and highest quality study, 1, discusses the current landscape and future perspectives of second-generation anti-amyloid monoclonal antibodies for Alzheimer's disease but does not mention sex-based differences in efficacy.

Key Points

  • The provided studies focus on the mechanisms, outcomes, and limitations of second-generation anti-amyloid monoclonal antibodies for the clinical treatment of Alzheimer's disease.
  • None of the studies directly compare the efficacy of amyloid monoclonal antibodies between sexes.
  • The studies discuss the importance of targeting amyloid-β peptide, tau protein, and neuroinflammation in the treatment of Alzheimer's disease.
  • The U.S. Food and Drug Administration has approved three anti-amyloid monoclonal antibodies, aducanumab, lecanemab, and donanemab, for the treatment of Alzheimer's disease.

Clinical Implications

  • Clinicians should consider the potential benefits and risks of amyloid monoclonal antibodies when discussing treatment options with patients.
  • Further research is needed to determine if there are any sex-based differences in the efficacy of amyloid monoclonal antibodies.
  • The provided studies emphasize the importance of patient-centered informed decision-making and comprehensive discussions with patients and care partners regarding treatment expectations and potential risks.

References

Related Questions

What are the types and incidence of immune-related adverse effects of anti-amyloid monoclonal antibody (mAb) treatment for Alzheimer's disease (AD)?
What are immune treatments for Alzheimer's (Alzheimer's disease)?
For a patient over 65 with mild cognitive impairment or mild dementia due to Alzheimer’s disease and confirmed amyloid‑β plaques, what are the FDA‑approved disease‑modifying therapies, their dosing regimens, and required monitoring?
Does Belsomra (suvorexant) help Alzheimer's disease?
What is the role of monoclonal antibody (mAb) treatment, such as aducanumab (aducanumab), in managing Alzheimer's disease?
What is the recommended follow-up for a patient with a 5mm tubular adenoma in the ascending colon and a 5mm hyperplastic polyp in the sigmoid colon?
What is the recommended follow-up for a hyperplastic polyp?
What is the relationship between Hereditary Hemochromatosis, Vitamin B12 deficiency, and Subacute Combined Degeneration (SCD) of the spinal cord?
What is the clinical significance of a rising M-protein (Monoclonal protein) level from 0.1 to 0.3 grams per deciliter (g/dL) in a patient with Monoclonal Gammopathy of Undetermined Significance (MGUS), with stable Beta-2 microglobulin (β2 microglobulin), Kappa (κ) chains, and Lambda (λ) chains?
How long is infectious mononucleosis (mono) contagious?
What is the differential diagnosis between fibrotic lung changes and Chronic Obstructive Pulmonary Disease (COPD) in an obese patient with normal Pulmonary Function Tests (PFTs) who still requires supplemental oxygen?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question